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Abstract
Aims Using compartment modelling, we assessed the time delay between blood glucose and sensor glucose measured by the
Guardian RT continuous glucose monitoring system in young subjects with Type 1 diabetes (T1D).
Methods Twelve children and adolescents with T1D treated by continuous subcutaneous insulin infusion (male ⁄ female 7 ⁄5;
age 13.1  4.2 years; body mass index 21.9  4.3 kg ⁄m2; mean  sd) were studied over 19 h in a Clinical Research Facility.
GuardianRT was calibrated every 6 h and sensor glucose measured every 5 min. Reference blood glucose was measured every
15 min using a YSI 2300 STAT Plus Analyser. A population compartment model of sensor glucose–blood glucose kinetics was
adopted to estimate the time delay, the calibration scale and the calibration shift.
Results The population median of the time delay was 15.8 (interquartile range 15.2, 16.5) min, which was corroborated by
correlation analysis between blood glucose and 15-min delayed sensor glucose. The delay has a relatively low intersubject
variability, with 95% of individuals predicted to have delays between 10.4 and 24.3 min. Population medians (interquartile
range) for the scale and shift are 0.800 (0.777, 0.823) (unitless) and 1.66 (1.47, 1.84) mmol ⁄ l, respectively.
Conclusions In young subjects with T1D, the total time delay associated with the Guardian RT system was approximately
15 min. This is twice that expected on physiological grounds, suggesting a 5- to 10-min delay because of data processing. Delays
above 25 min are rarely to be observed.
Diabet. Med. 27, 117–122 (2010)
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Abbreviations CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin; IQR, interquartile range; PR95,
95% predictive range; T1D, Type 1 diabetes
Introduction
In the last two decades, numerous approaches to minimally
invasive continuous glucose monitoring (CGM) have been
proposed and at least four devices have become commercially
available [1–4]. A clinical benefit of CGM has been suggested
[5,6]. Most recently, it has been demonstrated that CGM
improves glycaemic control in adults with Type 1 diabetes
(T1D), although some barriers to effectiveness of CGM in
children and adolescents with T1D remain [7].
Most CGM devices utilize a biosensor embedded
subcutaneously to measure interstitial glucose [8]. It is
generally accepted that a concentration gradient exists between
interstitial glucose and blood glucose with a range between 20
and 110% of blood glucose [9,10], although a 60% gradient is
most likely [11]. CGM devices correct for this gradient through
calibration based on self-monitored capillary glucose measure-
ments. An impediment to real-time accurate CGM tracing is the
existence of a physiological delay between blood glucose and
interstitial glucose which has been estimated to be approximately
5–10 min [12], although a wider range may be possible [13,14].
In addition to the physiological delay, data processing and
filtering [15,16] may result in a ‘technological’ delay. The
combined (total) delay is then observed by CGM users.
At present, these combined delays are not known or are poorly
understood for commercial CGM devices, but their
Correspondence to: Dr Chen Wei, MRC Biostatistics Unit, Institute of Public
Health, University Forvie Site, Robinson Way, Cambridge, CB2 0SR, UK.
E-mail: chen.wei@mrc-bsu.cam.ac.uk
Re-use of this article is permitted in accordance with the Terms and
Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_
Terms
DIABETICMedicine
DOI:10.1111/j.1464-5491.2009.02887.x
ª 2010 The Authors.
Journal compilation ª 2010 Diabetes UK. Diabetic Medicine, 27, 117–122 117
characterization may be important in determining the clinical
utility of CGM devices and facilitating more informative user
training. In the present study, we employ a population-based
compartment modelling approach [17–19,31] to determine the
time delay associated with the GuardianRT system (Medtronic
MiniMed, Northridge, CA, USA) [20] in young subjects with
T1D and to complement existing knowledge about numerical
and clinical accuracy of this CGM device [21–24].
Subjects and methods
Subjects and study protocol
Twelve children and adolescents withT1D treated by continuous
subcutaneous insulin infusion [male ⁄ female 7 ⁄5; age
13.1  4.2 years; body mass index (BMI) 21.9  4.3 kg ⁄m2;
glycated haemoglobin (HbA1c) 8.7  2.0%; duration of
diabetes 7.0  4.5 years; duration on pump 1.9  1.1 years;
total daily insulin 0.89  0.27 U ⁄kg ⁄day; mean  sd]
participated in a clinical research study conducted at the
Wellcome Trust Clinical Research Facility, Addenbrooke’s
Hospital, University of Cambridge, UK. Participants and, as
appropriate, their carers gave informed consent ⁄assent. The
study was approved by the Ethics Committee.
At least 24 h prior to the study, a glucose sensor was inserted
and, following a run-in period and calibration as suggested by the
manufacturer, the Guardian RT CGM system measured sensor
glucose every 5 min. On arrival at the Clinical Research Facility
at 16.00 h, a cannula was inserted in a vein of one arm and kept
patent with sodium chloride 0.9%. Blood samples were taken
every 15 min from 17.00 h until 12.00 h the following day.
Blood was collected into a 1.3-ml tube containing sodium
fluoride. The reference blood glucose concentrations were
measured using a YSI 2300 STAT Plus Analyser (YSI Life
Sciences, Yellow Springs, OH, USA). Two meals were eaten at
18.00 h and 08.00 h the following morning to maintain a
normal carbohydrate intake. Prandial insulin boluses were given
with the meal. The Guardian RT was calibrated at
approximately 17.00 h and then every 6 h using blood glucose
measured on the YSI.
Interstitial glucose kinetics
A compartmental model [25,26] was used to describe the
relationship between blood glucose and interstitial glucose. The
model is expressed by a linear differential equation
dIGn
dt
¼ 1
s
ðBG IGnÞ ð1Þ
where IGn (mmol ⁄ l) is normalized interstitial glucose equalling
bloodglucose at steady state; the time constant s (min) represents
the delay between blood glucose and normalized interstitial
glucose.
The intended clinical use of Guardian RT is to approximate
blood glucose. The calibration procedure residing on Guardian
RT aims to eliminate the blood-to-interstitial glucose gradient
known to be approximately 60% at steady state [11], to mitigate
the delay and to provide overall accurate glucose measurements.
Calibration and measurement error
IGn is obtained by numerically solving Eqn (1) with s as an
unknown parameter to be estimated and BG given by linearly
interpolating between the observed values. The unknown time
delay s is allowed to vary between individuals but is assumed
constant for any given individual. To account for calibration, we
assume that sensor glucose is linearly related to IGn, with
intercept and gradient terms referred to throughout as the
calibration shift and scale factor, respectively. These are
unknown parameters, which are allowed in our model to differ
between both individuals and calibration periods. Any residual
discrepancies between the observed and modelled sensor glucose
values are then assumed to be normally distributed with mean
zero and with an unknown variance (to be estimated) that also
varies between both individuals and calibration periods.
Data analysis
All of the aforementioned unknown parameters are assumed to
arise from ‘population distributions’ that characterize the mean
and variability of the individual- and calibration-period-specific
values. We use a population-based parameter estimation method
in which all of the individual-, calibration-period- and
population-level parameters are estimated simultaneously,
which allows for more efficient usage of the information
contained in the data set and typically leads to more reliable
inferences. More details about the data analysis are provided in
the Supporting Information (Appendix S1).
Results
Glucose profiles, glucose kinetics, and model fit
The reference blood glucose levels were 8.0  2.8 mmol ⁄ l
(mean  sd) ranging from 3.0 to 18.0 mmol ⁄ l. Overall, 7% of
the time blood glucose was £ 3.9 mmol ⁄ l, 51% of time blood
glucose was between 3.9 and 8.0 mmol ⁄ l and 42% of the time
blood glucose was ‡ 8.0 mmol ⁄ l.
Differences between blood and sensor glucose were identified
as demonstrated in Fig. 1, which shows blood and sensor glucose
profiles for individual number 2. Mean sensor glucose is higher
than blood glucose: the mean  sd difference between sensor
and blood glucose, in all individuals, is 0.24  1.3 mmol ⁄ l. This
results primarily from a positive calibration shift and a
calibration scale factor below unity as reported for the majority
of calibrationperiods. Sensor glucosegenerally lags behind blood
glucosebut, importantly, thedegreeof lagappears to changeover
time. However, the apparent lag reflects the extent of shifting and
scaling as a result of calibration as well as the actual (kinetic) lag.
Although our model is somewhat complicated, it aims to break
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down this apparent lag into its component parts. Hence, we may
disentangle the effects of calibration and kinetic delay and better
characterize the observed differences between blood and sensor
glucose than would be possible through estimation of some
‘average’ apparent lag, via, for example, minimization of the
differences between blood glucose and time-shifted sensor
glucose [8,24]. Aside from providing a better understanding of
the underlying processes, this represents an important step
towards facilitating realistic prediction of blood glucose-sensor
glucose profiles, which can be used, for example, to test glucose
control algorithms [27]. Note that the good fit obtained by
assuming a constant time lag s, as shown by the solid line in
Fig. 1, demonstrates little or no evidence of a time-varying
kinetic delay. The model fit for this individual is fairly typical.
Population analysis
Individual and population estimates for the time delay between
blood and sensor glucose are given in Table 1, along with their
interquartile ranges (IQR), which show the degree of precision.
The individual delays range from 10.8 to 21.4 min. The
populationmediandelay is15.8 min,withanIQRof (15.2,16.5)
min. To corroborate our results, we calculated the correlation
coefficientbetweenbloodglucose andsensorglucoseusingapure
time lag of 0, 5, 10, 15 and 20 min. This was carried out by
delaying sensor glucose in 5-min intervals. This is possible as
sensor glucose is reported by Guardian RT with a 5-min
resolution. With a value of 0.937, the correlation coefficient
peaks at 15-min delay, supporting our model-based estimate of
the time delay.
The variability in the time delay is most usefully expressed
by a predictive distribution for a new individual’s time delay.
This is readily obtained from our analysis. Expressed as 2.5,
25, 50, 75 and 97.5% percentiles, the delay is 10.4, 13.9,
15.8, 18.1 and 24.3 min, respectively. Hence, with probability
0.95 a new individual’s time delay will lie between 10.4 and
24.3 min.
The population-based analysis also provides population and
individual estimates for the calibration scale factor and shift, and
the standard deviation r of the residual errors. Population
medians (IQR) for the scale and shift are 0.800 (0.777, 0.823)
(unitless) and 1.66 (1.47, 1.84) mmol ⁄ l, respectively. There exists
substantial variability between calibration periods, again best
expressed through predictive distributions. Ninety-five per cent
predictive ranges (PR95) for scale and shift are (0.437, 1.46)
(unitless) and (–2.07, 5.41) mmol ⁄ l, respectively. Further
statistical analyses suggest that the scale and shift are not
characteristics of an individual; that is, none of the variability
among their values appears to be attributable to differences
between patients. The population median (IQR) residual
standard deviation r is 0.250 (0.236, 0.265) mmol ⁄ l, whereas
the PR95 for new rs is (0.0736, 0.842) mmol ⁄ l.
Discussion
Our results indicate that, in young subjects with T1D, the delay
between blood glucose and sensor glucose reported by the
Guardian RT CGM system is approximately 16 min and this
result is supported by the correlation analysis. The highest
correlation with blood glucose is observed when sensor glucose is
delayed by 15 min. The delay has a relatively low intersubject
variability, with 95% of individuals predicted to have delays
between 10.4 and 24.3 min.
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FIGURE 1 Blood glucose (dashed line), sensor glucose reported by
GuardianRT (vertical bar line) and model fit (solid line) in a young subject
with Type 1 diabetes (individual number 2). Four vertical dashed lines
indicate the times at which calibration was carried out, starting at
approximately 17.00 h and then every 6 h. The estimated time delay
betweenbloodandsensorglucoses for this subject is15.2 min.Estimates for
the calibration shift and scale factor in each of the five calibration periods
are: 3.48, 1.96, 1.73, 1.74,)0.347 mmol ⁄ l (shift); and 0.784, 0.882, 0.826,
0.814, 1.04 (scale; unitless).
Table 1 The median and interquartile range (reflecting accuracy of
estimation) of the time delay s
Subject number
s (min)
Median 25% percentile 75% percentile
1 16.1 15.5 16.8
2 15.2 14.7 15.6
3 15.6 14.6 16.8
4 15.7 14.5 16.9
5 19.9 19.4 20.4
6 14.3 13.8 14.9
7 16.7 16.2 17.1
8 16.8 16.0 17.6
9 21.4 20.2 22.5
10 10.8 10.4 11.2
11 14.2 13.9 14.5
12 16.2 15.4 17.0
Population 15.8 15.2 16.5
Individual and population estimates are shown.
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The delay comprises two components. The physiological delay
reflects the diffusion of glucose from the plasma to the interstitial
fluid and the data processing component reflects filtering the
measurement noise and smoothing the sensor signal by software
residing on the Guardian RT. The consensus is that the
physiologicaldelay inadults is approximately5–10 min [25],but
may be shorter in young subjects withT1D. This suggests that the
error filtering and data smoothing component of the delay is
5–10 min or longer and therefore of at least the same magnitude
as the physiological delay. Therefore, the apparent delay cannot
be deduced simply from the physiological delay, but is device-
dependent, as different manufactures will use different data
processing techniques.
Considering the population median scale factor at 0.800
(unitless) and the median shift at 1.66 mmol ⁄ l, the Guardian
RT calibration procedure will tend to match blood and sensor
glucose at approximately 8.3 mmol ⁄ l. This is in agreement with
a multi-centre study assessing numerical accuracy of Guardian
RT for children with T1D [21]. Below this threshold,
Guardian RT is likely to overestimate and above the
threshold to underestimate blood glucose. However, high
variability between calibration periods exists and this appears
not to be subject specific. In our study, we used the highly
accurate YSI for calibration. The use of less accurate glucose
meters will further increase this variability.
Recently, a delay of 21  5 min has been reported for the
Guardian RT in adults with T1D [24]. This appears to be
longer than that reported in our results. However, the longer
delay was estimated using an inappropriate methodology, i.e.
the estimation involved ‘holding the YSI curve constant and then
time shifting the CGM curve to minimize the error between YSI
and CGM’ [24]. This visually guided procedure has three main
limitations: (i) it is possibly subjective; (ii) it neglects the effects of
scaling and shifting because of calibration on the differences
between blood and sensor glucose: ideally these would be
removed before (or simultaneously with) time-shifting, but their
magnitudes are unknown; and (iii) it does not quantify the
degree of uncertainty associated with the resulting delay
estimate, which can lead to an unreliable characterization of
the distribution of delays throughout the population of interest,
as discussed below. We were able to separate the effects of
calibration and delay, determining the scale, shift and underlying
lag using a statistically rigorous approach without the need for
subjective decision making. The resulting parameter estimates
better characterize the observed differences between blood and
sensor glucose.
The additional strength of our approach is that we estimate
individual andpopulation values in aone-stageprocess known as
a hierarchical analysis [31]. This typically yields more reliable
inferences than the alternative two-stage approach, where each
subject is analysed independently and the population mean and
variability are derived from the individual estimates. Any
uncertain individual estimates, which may be somewhat
unrepresentative of the underlying ‘true’ values, can unduly
influence estimation of the mean and variability as the
uncertainty is not taken into account, i.e. individual estimates
contribute in the same way irrespective of their uncertainty.
Typically, the two-stage estimate of the population variance is
inflated when there is substantial uncertainty. By contrast, the
one-stage approach allows ‘borrowing of strength’ across
individuals, whereby well-determined individual estimates
contribute more to the estimation of the population
characteristics, and the information provided about these
characteristics, in turn, helps strengthen the less well-
determined individual estimates. This has the effect of
increasing robustness of the population estimates as well as
reining in the more unreliable individual estimates. In the context
of the present study, subjects with a relatively constant or slowly
changing glucose profile provide an uncertain estimate of the
delay. Suchuncertaintymayexplain thehighvariability and large
delays obtained previously from two-stage analyses [13,14].
The expected differences between sensor and blood glucose
depend on the rate of change of the glucose concentration. When
glucose is changing rapidly, differences will increase. This may be
perceived as an increase of the ‘apparent’ delay although the
‘kinetic’ delay remains unchanged. Our estimate of the kinetic
delay allows the differences between sensor and blood glucose to
be assessed. As an illustration, consider three different rates of
glucose increase:0.025,0.05and0.1 mmol ⁄ l ⁄min (the latter two
rates are used by the Guardian RT system to denote rapid or
very rapid glucose change). The population median delay
(15.8 min) then corresponds to differences between sensor
glucose and blood glucose of 0.395, 0.790 and 1.58 mmol ⁄ l,
respectively. Note that the difference increases in proportion to
the rate of change of glucose even although the underlying delay
is constant. Corresponding differences for the 2.5 and 97.5%
percentiles (10.4 min,24.3 min)of thepredictivedistribution for
delay are (0.260, 0.608), (0.52, 1.22) and (1.04, 2.43) mmol ⁄ l,
respectively. In practice, the differences will be inflated by the
calibration error, which is expected to be relatively constant over
a calibration period.
Using the model we developed, we obtained an excellent fit to
sensor glucose in most individuals. However, the residual error
was occasionally consistently positive or consistently negative,
indicating the presence of unmodelled processes of uncertain
origin. Our model could be expanded by assuming an
autoregressive process for the residual errors instead of
assuming them to be independent, or other approaches could
be used to handle autocorrelated residuals [28].
The main objective of our study was to investigate the delay
between blood and sensor glucose, which, in principle, should be
independent from the way blood glucose is measured. Compared
with a standard glucometer, the YSI provides more accurate
measurements and thus the assessment of the delay should be
highly accurate. However, additional errors associated with the
use of capillary blood glucose meters may cause higher
discrepancies to be observed in daily practice.
Our study complements the traditional assessment of
clinical and numerical accuracy utilizing the error grid
analysis, the assessment of absolute and relative absolute
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deviations and the correlation analysis [8,22,29,30]. In
particular, our analysis provides useful information about
the expected delay between blood and sensor glucose and the
source and extent of the calibration error. The results were
obtained in a heterogeneous population of young subjects
with T1D, e.g. age ranged from 5 to 18 years, HbA1c from
6.5 to 13.3% and the total daily dose as a marker of insulin
sensitivity from 0.50 to 1.29 U ⁄kg ⁄day.
In conclusion, we adopted a population-based modelling
approach to describe the delay between blood and sensor
glucose reported by Guardian RT. Our results suggest a
typical delay of 15.8 min, with 95% of individuals predicted
to have delays in the range 10.4–24.3 min. The delay is
double that expected on physiological grounds, suggesting
5- to 10-min delays as a result of the data processing software
residing on Guardian RT.
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